Apr 18, 2024 10:53 JST

Source: Eisai

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
As a Part of FY2024 Commendation For Science and Technology by MEXT

TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms” has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) grants this award to individuals who have made remarkable achievements regarding research, development, and knowledge enhancement in the field of science and technology, with the aim of encouraging those who engage in the field and raising the standard of Japanese science and technology. This award is presented to individuals who have completed original research and development projects with high potential to contribute to the advancement of science and technology in Japan.

Teiji Kimura, Ph.D., Senior Group Officer of Eisai, and Prof. Takeshi Iwatsubo, Graduate School of Medicine and Faculty of Medicine, the University of Tokyo, were awarded this prize in recognition of the breakthrough achieved through the creation of the anti-Aβ protofibril antibody lecanemab, that was accomplished by a combination of the efforts of academia, in particular the establishment of the theoretical basis for Aβ- targeted therapy based on functional genetics and the development of a clinical trial environment incorporating imaging and biomarkers based on large-scale clinical observational studies such as J-ADNI (Japanese Alzheimer's Disease Neuroimaging Initiative), and our corporate commitment to anti-Aβ drug discovery research.

Award Theme

The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms

Awardees

Prof. Takeshi Iwatsubo (Graduate School of Medicine and Faculty of Medicine, the University of Tokyo) Teiji Kimura (Global Alzheimer's Disease Head, Global Collaboration Network Lead, Senior Group Officer, Eisai Co., Ltd.)

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
February 14 2025 11:09 JST
 
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
February 03 2025 16:23 JST
 
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
January 28 2025 08:46 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
January 22 2025 16:18 JST
 
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
January 15 2025 09:03 JST
 
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
January 07 2025 08:14 JST
 
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
December 23 2024 16:22 JST
 
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
December 11 2024 13:45 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
December 05 2024 10:22 JST
 
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
November 28 2024 15:26 JST
 
More Press release >>

Latest Press Release


More Latest Release >>